Capecitabine Plus Pyrotinib Versus Capecitabine Plus Trastuzumab and Pertuzumab in the First-line Treatment of HER2-positive Metastatic Breast Cancer

Clinical trial NCT04246502 · UNKNOWN

Trial details

NCT number: NCT04246502
Sponsor: Shandong Cancer Hospital and Institute
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer

Start date: 2020-01-01
Primary completion: 2022-12-01
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.